Mabion S.A. (FRA:272)
1.594
-0.046 (-2.80%)
At close: Dec 19, 2025
Mabion Revenue
Mabion had revenue of 4.08M PLN in the quarter ending September 30, 2025, with 691.47% growth. This brings the company's revenue in the last twelve months to 14.81M, down -86.63% year-over-year. In the year 2024, Mabion had annual revenue of 69.02M, down -54.50%.
Revenue (ttm)
14.81M PLN
Revenue Growth
-86.63%
P/S Ratio
7.56
Revenue / Employee
69.54K PLN
Employees
213
Market Cap
26.23M EUR
Revenue Chart
* This company reports financials in PLN.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 69.02M | -82.66M | -54.50% |
| Dec 31, 2023 | 151.68M | -12.30M | -7.50% |
| Dec 31, 2022 | 163.98M | 127.92M | 354.72% |
| Dec 31, 2021 | 36.06M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mercedes-Benz Group AG | 136.97B |
| Bayerische Motoren Werke Aktiengesellschaft | 136.42B |
| Deutsche Telekom AG | 121.02B |
| Allianz SE | 105.02B |
| Deutsche Post AG | 84.05B |
| Siemens Aktiengesellschaft | 78.91B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.10B |
| Siemens Energy AG | 39.08B |
Mabion News
- 5 years ago - Spark Therapeutics Further Strengthens Technical Expertise with Appointment of Cynthia Pussinen as Chief Technical Officer - GlobeNewsWire
- 5 years ago - Spark Therapeutics Announces First Participant Dosed in Phase 1/2 Study of Investigational Gene Therapy for Late-Onset Pompe Disease - GlobeNewsWire
- 6 years ago - GAMCO Investors Exits Viacom, Spark Therapeutics - GuruFocus
- 6 years ago - Regulators Give Roche Green Light For $4.3B Spark Therapeutics Acquisition - Benzinga
- 6 years ago - Roche to complete $4.3 billion Spark deal as regulators give all clear - Reuters
- 6 years ago - U.S. antitrust enforcers give Roche approval to buy Spark Therapeutics - Reuters
- 6 years ago - Spark Therapeutics Wins Prix Galien USA Award for LUXTURNA® (voretigene neparvovec-rzyl) as Best Biotechnology Product - GlobeNewsWire
- 6 years ago - FTC staff recommends approval of Roche deal for Spark: report - Reuters